title: Neuroleptic malignant syndrome: need for early diagnosis and therapy.
abstract: BACKGROUND
  Neuroleptic Malignant Syndrome (NMS) is a medical entity that has received little attention in the clinical settings in Pakistan. The aim of our study was to review the predisposing factors, outcomes and characteristics of in-patients diagnosed with NMS.
  
  
  METHODS
  We performed a retrospective chart review of all cases (age >15 years) at a tertiary care center in Karachi between January 01, 1990 and November 30, 2001, diagnosed using ICD 10 coding. Data was collected using a standardized data entry form and statistical analysis was performed using Epi Info 6, Version 6.02.
  
  
  RESULTS
  There were a total of 20 patients diagnosed with NMS (11 male and 9 female) in our study with a mean age of 46.6 +/- 15.9 years. Haloperidol was the most frequently responsible neuroleptic. Of the 18 patients on a neuroleptic, most developed NMS after 8 weeks of therapy. There were 5 mortalities all of which were associated with septic shock. Fourteen patients recovered completely from the episode and did not have any neurologic sequelae.
  
  
  CONCLUSIONS
  NMS is an important preventable clinical entity. Early diagnosis and judicious use of antipsychotics is warranted to prevent mortality and heightened morbidity.
authors.affiliation: Department of Medicine, Section of Neurology, The Aga Khan University, Karachi.
authors.forename: Humaira M
authors.initials: HM
authors.lastname: Khan
authors.forename: Nadir A
authors.initials: NA
authors.lastname: Syed
authors.forename: Mughis
authors.initials: M
authors.lastname: Sheerani
authors.forename: Bhojo
authors.initials: B
authors.lastname: Khcalani
authors.forename: Ayeesha
authors.initials: A
authors.lastname: Kamal
authors.forename: Mohammad
authors.initials: M
authors.lastname: Wasay
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000009:adverse effects*; D005260:Female; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D038801:International Classification of Diseases; D008297:Male; D008875:Middle Aged; D019964:Mood Disorders / Q000188:drug therapy; D009459:Neuroleptic Malignant Syndrome / Q000175:diagnosis / Q000503:physiopathology* / Q000628:therapy; D012189:Retrospective Studies; D012559:Schizophrenia / Q000188:drug therapy; D012772:Shock, Septic / Q000401:mortality
chemical_list: D014150:Antipsychotic Agents; D006220:Haloperidol